We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+13.54%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.12B
AUM Growth
-$493M
Cap. Flow
-$785M
Cap. Flow %
-15.35%
Top 10 Hldgs %
51.39%
Holding
136
New
20
Increased
23
Reduced
33
Closed
42

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$101M
2
RLAY icon
Relay Therapeutics
RLAY
+$70.2M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$59.9M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$39.8M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$33.2M

Top Sells

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$122M
2
ACLX
Arcellx
ACLX
+$95.6M
3
BSX icon
Boston Scientific
BSX
+$93.3M
4
FOLD
Amicus Therapeutics
FOLD
+$90.7M
5
ATXS
Astria Therapeutics
ATXS
+$84.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NAUT icon
26
Nautilus Biotechnolgy
NAUT
$221M
$48.9M 0.95%
12,594,211
– –
CTMX icon
27
CytomX Therapeutics
CTMX
$788M
$47.5M 0.93%
10,098,824
+418,639
+4% +$2.12M
ANRO icon
28
Alto Neuroscience
ANRO
$1.07B
$45.2M 0.88%
2,009,893
+225,500
+13% +$4.18M
ENGN icon
29
enGene Therapeutics
ENGN
$122M
$39.7M 0.78%
5,827,506
-41,570
-0.7% -$370K
IMVT icon
30
Immunovant
IMVT
$8.27B
$39.7M 0.78%
1,597,383
-397,507
-20% -$10.3M
ISRG icon
31
Intuitive Surgical
ISRG
$122B
$39.4M 0.77%
85,419
-2,500
-3% -$1.26M
IONS icon
32
Ionis Pharmaceuticals
IONS
$8.99B
$37.8M 0.74%
+504,000
New +$39.8M
DAWN
33
DELISTED
Day One Biopharmaceuticals
DAWN
$37.6M 0.74%
+1,755,799
New +$24.7M
ABVX
34
Abivax
ABVX
$11.9B
$36.6M 0.72%
328,884
-129,459
-28% -$15.3M
CRVS icon
35
Corvus Pharmaceuticals
CRVS
$1.25B
$33.5M 0.66%
2,292,441
+1,600,000
+231% +$25.5M
RGEN icon
36
Repligen
RGEN
$8.31B
$33.1M 0.65%
280,541
-35,000
-11% -$4.89M
JAZZ icon
37
Jazz Pharmaceuticals
JAZZ
$15.5B
$32.1M 0.63%
170,000
– –
DMRA
38
Damora Therapeutics
DMRA
$1.94B
$31.7M 0.62%
+1,223,000
New +$31.4M
XFOR icon
39
X4 Pharmaceuticals
XFOR
$360M
$27.8M 0.54%
6,737,648
+423,196
+7% +$1.59M
GH icon
40
Guardant Health
GH
$20.7B
$27.7M 0.54%
300,000
+140,000
+88% +$14.1M
DRUG
41
Bright Minds Biosciences
DRUG
$747M
$27.5M 0.54%
377,544
-71,746
-16% -$5.78M
IVVD icon
42
Invivyd
IVVD
$219M
$27.1M 0.53%
20,859,303
-925,863
-4% -$1.7M
SION
43
Sionna Therapeutics
SION
$2.23B
$26.4M 0.52%
658,439
-520,659
-44% -$19.9M
AXSM icon
44
Axsome Therapeutics
AXSM
$11.8B
$25.3M 0.5%
149,950
+1,050
+0.7% +$181K
RVMD icon
45
Revolution Medicines
RVMD
$39.6B
$25.1M 0.49%
+258,600
New +$26.1M
SABS icon
46
SAB Biotherapeutics
SABS
$271M
$24.6M 0.48%
6,431,743
+5,628,533
+701% +$22.4M
BLTE
47
Belite Bio
BLTE
$6.02B
$24.2M 0.47%
151,979
-262,260
-63% -$44.1M
TENX icon
48
Tenax Therapeutics
TENX
$420M
$23.2M 0.45%
1,447,782
+1,008,640
+230% +$13.6M
AXGN icon
49
Axogen
AXGN
$2.12B
$23.1M 0.45%
697,312
-86,828
-11% -$2.82M
VRDN icon
50
Viridian Therapeutics
VRDN
$1.99B
$22.9M 0.45%
1,170,829
-1,871,874
-62% -$55.6M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Perceptive Advisors held 136 positions worth $5.12B, down 8.8% from $5.61B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Perceptive Advisors withdrew a net $785M in Q1 2026, closing 42 positions and reducing 33 holdings. Its most notable exit was Exact Sciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Ionis Pharmaceuticals worth $37.8M.

  • Perceptive Advisors's largest Q1 2026 buy was Ionis Pharmaceuticals: 504,000 shares worth $37.8M.
  • Perceptive Advisors added most to Ascendis Pharma A/S in Q1 2026, an estimated $101M increase.
  • Perceptive Advisors's biggest Q1 2026 reduction was Apogee Therapeutics, cutting an estimated $57.4M.
  • Perceptive Advisors fully exited Exact Sciences in Q1 2026, selling an estimated $122M.
  • Perceptive Advisors's ten largest holdings make up 51% of its $5.12B portfolio in Q1 2026.
  • Perceptive Advisors opened 20 new positions and closed 42 in Q1 2026.
  • Perceptive Advisors's portfolio value fell 8.8% quarter-over-quarter to $5.12B.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.